Remedy Cell

Remedy Cell is a biopharmaceutical company leveraging scientific advances in cell-derived therapies to develop first-in-class breakthrough treatments for patients with complex fibrotic diseases. The company’s lead product, RC-0315, for the treatment of idiopathic pulmonary fibrosis (IPF), has already achieved highly encouraging preclinical results, with the goal of first entering human trials in early 2025. IPF is a severe chronic disease that affects the tissue surrounding the air sacs or alveoli in the lungs. IPF is an "orphan disease," with 100,000 patients in the United States and approximately 110,000 patients in Europe. There is currently no cure, and IPF patients typically survive no more than 2-5 years after diagnosis. There is an urgent need for a treatment that can effectively reduce fibrosis and restore lung function.